{"organizations": [], "uuid": "e75d0fb21d25ec52406bc2eba3856d67c093eeb1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/01/globe-newswire-agtc-to-host-second-quarter-financial-results-conference-call-and-webcast-on-february-9-2018.html", "country": "US", "domain_rank": 767, "title": "AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-02-02T00:05:00.000+02:00", "replies_count": 0, "uuid": "e75d0fb21d25ec52406bc2eba3856d67c093eeb1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/01/globe-newswire-agtc-to-host-second-quarter-financial-results-conference-call-and-webcast-on-february-9-2018.html", "ord_in_thread": 0, "title": "AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018", "locations": [], "entities": {"persons": [{"name": "genetic technologi", "sentiment": "negative"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "fla.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}, {"name": "gainesville", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "agtc", "sentiment": "negative"}, {"name": "eastern time", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended December 31, 2017 before the market opens on Friday, February 9, 2018. AGTC management beginning at 8:00 am Eastern Time that day to review results and provide a corporate update.\nTo access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The passcode is 13676228. A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events.cfm . Please log in approximately 10 minutes prior to the scheduled start time.\nThe archived webcast will be available in the Events and Presentations section of the company's website.\nAbout AGTC\nAGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRS and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.\nAGTC IR/PR CONTACTS:\nDavid Carey (IR) or Tom Vickery (PR)\nLazar Partners Ltd.\nT: (212) 867-1768 or (646) 871-8482\ndcarey@lazarpartners.com or tvickery@lazarpartners.com\nCORPORATE CONTACTS:\nBill Sullivan\nChief Financial Officer\nApplied Genetic Technologies Corporation\nT: (617) 843-5728\nbsullivan@agtc.com\nStephen Potter\nChief Business Officer\nApplied Genetic Technologies Corporation\nT: (617) 413-2754\nspotter@agtc.com\nSource:Applied Genetic Technologies Corporation", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/542616ce-01ae-469d-b4ff-5285f7e0584e", "https://www.globenewswire.com/Tracker?data=NaurMXBdb428qoyZMUnw1FVxn66sQqCaCJto2uhjvfVcVo3Pa1KBVJQRqkNOoqcsRJaZRZSPyJNHeY3j9lNl9odYq12lZinzRO98mOxM91H2a3dtutwhY7gL6zsjRavS", "http://ir.agtc.com/events.cfm", "https://www.globenewswire.com/Tracker?data=1uuzZeujn5Zw8w4xdZOQnjqHRi8Uxb9x1JCmLz_Bvc1DL8gWDn7fy2eOo7zTSskVtk5URcCuFmMNMjBbxjh6Dw==", "https://www.globenewswire.com/Tracker?data=RkIf3-gLWGGUrYtSuukKpg8deCwoXUnpOPR5XYuv0DMugWWOn4O-LL3dethMRW72CTkIIvPzVb7RDs9z_RIOxGBRs5O6XGJFcP_nINgpcBY=", "https://www.globenewswire.com/Tracker?data=zfIveKl3A34iREc_lYxr_F349wlPrD1Vsc7Qiz60AFcPkcBji_kRdwVgciUOoy7s3fCHL3BYgGYsxEnmwRe2Nakra7ml9ZUN_3y1AWqvo6U=", "https://www.globenewswire.com/Tracker?data=tj7_QDR6VwT9DDzMHxZgicTtQppm4gBvwjfHrd7lj9mpsi3z4k0LYM_RGFplJhcs9NR1I-Vls0RQpoBt3VbgGvKhDYUcuXCoKjiIOobrrzQ="], "published": "2018-02-02T00:05:00.000+02:00", "crawled": "2018-02-02T01:11:33.029+02:00", "highlightTitle": ""}